Novo Nordisk launches higher-dose Wegovy

Novo Nordisk has introduced a higher-dose version of its popular weight-loss drug, Wegovy, in the United States. The new 2-milligram dose, branded as Wegovy HD, received approval last month under the FDA's National Priority Review Voucher program. This expanded offering aims to provide more treatment options for patients managing obesity. The availability of the higher-dose formulation is expected to enhance patient outcomes and further solidify Novo Nordisk's market leadership in the GLP-1 drug class.